Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.96 USD
Change Today +0.0183 / 1.95%
Volume 94.2K
NURO On Other Exchanges
Symbol
Exchange
NURO is not on other exchanges.
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

neurometrix inc (NURO) Snapshot

Open
$0.91
Previous Close
$0.94
Day High
$0.96
Day Low
$0.91
52 Week High
07/8/14 - $3.15
52 Week Low
06/18/15 - $0.84
Market Cap
22.1M
Average Volume 10 Days
83.2K
EPS TTM
$-1.67
Shares Outstanding
23.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NEUROMETRIX INC (NURO)

Related News

No related news articles were found.

neurometrix inc (NURO) Related Businessweek News

No Related Businessweek News Found

neurometrix inc (NURO) Details

NeuroMetrix, Inc., a medical device company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders, such as those associated with carpal tunnel syndrome, lumbosacral disc disease and spinal stenosis, and diabetes. The company develops wearable medical technology and point-of-care tests that help patients and physicians manage chronic pain, nerve diseases, and sleep disorders. Its marketed products include Quell, a wearable device for relief of chronic pain, such as nerve pain due to diabetes and lower back problems; the SENSUS pain therapy device, a prescription neurostimulation device based on transcutaneous electrical nerve stimulation for relief of chronic, intractable pain; DPNCheck, a test used to evaluate systemic neuropathies, such as diabetic peripheral neuropathy; and ADVANCE NCS/EMG system, a platform for the performance of traditional nerve conduction studies and invasive electromyography procedures for the assessment of carpal tunnel syndrome. The company distributes its products through its direct sales force and independent sales representatives to physicians, clinics, hospitals, managed care organizations, retail health businesses, and independent distributors consisting of primary care, internal medicine, orthopedic and hand surgeons, pain medicine physicians, neurologists, physical medicine and rehabilitation, physicians, and neurosurgeons primarily in the United States, Europe, Asia, and the Middle East. NeuroMetrix, Inc. was founded in 1996 and is headquartered in Waltham, Massachusetts.

32 Employees
Last Reported Date: 02/25/15
Founded in 1996

neurometrix inc (NURO) Top Compensated Officers

Founder, Chairman, Chief Executive Officer, P...
Total Annual Compensation: $647.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $437.4K
Senior Vice President and General Manager of ...
Total Annual Compensation: $156.1K
Compensation as of Fiscal Year 2014.

neurometrix inc (NURO) Key Developments

NeuroMetrix Inc. Launches Quell Wearable Pain Relief Technology

NeuroMetrix Inc. announced the full commercial launch of Quell, which is now available on the company’s product website at QuellRelief.com and at select physicians’ offices. Quell is an easy-to-use, over-the-counter chronic pain relief device. This wearable device utilizes NeuroMetrix’s patented, non-invasive nerve stimulation technology to provide 100% drug-free chronic pain relief. It is designed for people with painful diabetic neuropathy, sciatica, osteoarthritis and fibromyalgia, among other conditions. Worn just below the knee, Quell calibrates automatically for every user, determining the ideal therapeutic intensity of electrical nerve stimulation to provide optimal pain relief. Quell triggers a central inhibition effect that “turns down the volume” of pain signals by stimulating the sensory nerves, which causes the brain to release endogenous opioids that ultimately reduce pain signal transmission. Quell provides widespread pain relief and is more than twice as strong as ordinary TENS devices, which typically provide only localized pain relief.

NeuroMetrix Inc. to Start Shipping Quell™ Wearable Pain Relief Device in June 2015

NeuroMetrix Inc. reported that it anticipates commercial shipments of the Quell wearable pain relief device will begin in June 2015. Quell is an over-the-counter wearable pain relief device that utilizes proprietary non-invasive neurostimulation technology to provide relief from chronic pain. The device is designed for people with conditions such as diabetic nerve pain, low back and leg pain, fibromyalgia and pain associated with osteoarthritis. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain without a prescription. Users of the device have the option of using their smartphone to automatically track and personalize their pain therapy.

NeuroMetrix, Inc. Receives Non-Compliance Notice From NASDAQ

On April 30, 2015, NeuroMetrix, Inc. received a deficiency letter from The NASDAQ Stock Market LLC (NASDAQ) indicating that, as of March 31, 2015 the company’s reported stockholders’ equity of $1,681,643 did not meet the $2,500,000 minimum required to maintain continued listing, as set forth in NASDAQ Listing Rule 5550(b)(1), and that as of April 29, 2015 the company does not meet the alternatives of market value of listed securities or net income from continuing operations. The notification has no immediate effect on the listing of the company’s common stock on the Nasdaq Capital Market. Under NASDAQ rules, the company has 45 calendar days, or until June 15, 2015, to submit a plan to NASDAQ to regain compliance. If the company’s plan is accepted, NASDAQ can grant an extension of up to 180 calendar days, or until October 27, 2015, to evidence compliance. If the company fails to regain compliance, the company’s stock will be subject to delisting by NASDAQ. The company plans to raise additional capital in order to regain compliance with the continued listing requirements and has filed a registration statement on Form S-1 with the Securities and Exchange Commission to register equity securities for sale in an offering.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NURO:US $0.96 USD +0.0183

NURO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Natus Medical Inc $41.31 USD -0.98
View Industry Companies
 

Industry Analysis

NURO

Industry Average

Valuation NURO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.4x
Price/Book 4.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEUROMETRIX INC, please visit www.neurometrix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.